Adooq Bioscience Secures Over $60 Million in Series B+ Financing to Accelerate Global Expansion

VCBeat (WeChat ID: vcbeat) has learned that AMADOR BIOSCIENCE, a CRO specializing in translational science and clinical pharmacology, has announced the completion of its Series B+ financing round, raising over $60 million. The new round was led by Magic Stone Alternative Investment (MSA), with existing investors Sequoia China, Hillhouse Ventures, and Kaifeng Venture Capital participating. Notably, this marks the second financing round completed by AMADOR BIOSCIENCE within a few months.

Following the completion of its Series B financing in September 2021, AMADOR BIOSCIENCE entered an accelerated phase of global development: it established a branch in Shanghai, China; commenced construction of new facilities in California and Maryland, USA, to expand its bioanalytical services; set up a European subsidiary in Limburg, Belgium, while launching a school-enterprise collaboration with Hasselt University in Belgium to jointly establish a graduate training program in clinical pharmacology; and acquired the renowned U.S. quantitative pharmacology company Ann Arbor Pharmacometrics Group (A2PG), thereby deepening its clinical pharmacology services and rapidly expanding its team of professionals.

““AMADOR BIOSCIENCE’s vision is to become the global partner of choice for the successful R&D of innovative drugs. We are committed to providing international-standard translational science and clinical pharmacology services to biopharmaceutical companies in China, the United States, and Europe,” stated Dr. Wang Bing, Chairman and CEO of AMADOR BIOSCIENCE. “The company completed nearly $100 million in Series B and B+ financing within just a few months, which is akin to achieving the critical End-of-Phase 2 (EOP2) milestone in clinical drug development. We are deeply grateful to our investors for their trust in AMADOR BIOSCIENCE, as well as to our domestic and international clients, employees, and partners for their strong support of the company’s growth.”

The funds raised in this round will be primarily used to implement AMADOR BIOSCIENCE’s global development strategy, strengthen its end-to-end translational science service system with a focus on clinical pharmacology, expand laboratory services centered on bioanalysis globally, and develop business in clinical pharmacology trials and early-stage clinical R&D.

Founded in 2018, Amador Bioscience is driven by clinical pharmacology to facilitate new drug development, providing end-to-end translational science services that meet international standards. These services encompass development strategies and execution from preclinical stages through early-phase clinical trials, helping biopharmaceutical companies scientifically “select the right dose, the right target, and the right patients.” By adhering to global quality execution standards, Amador Bioscience enhances the success rate of new drug R&D. Its client base ranges from leading startup biotech firms to multinational pharmaceutical companies. Amador Bioscience currently operates facilities in multiple locations worldwide, including Pleasanton, CA; Ann Arbor, MI; Germantown, MD; and Richmond, VA in the United States; Hangzhou and Shanghai in China; and Limburg, Belgium in Europe.

Dr. Wang Bing, Chairman and CEO of AMADOR BIOSCIENCEstated: “We will further expand our team and business scale, apply AI technology to clinical data analysis, uphold and continuously optimize AMADOR BIOSCIENCE’s commitment to efficiency and quality, and build a professional, high-quality service system. We are deeply honored to have the trust and support of our customers, employees, and shareholders, and we believe that through collaborative efforts, we can transform AMADOR BIOSCIENCE into an engine of innovation and efficiency, accelerating the global development of innovative drugs.”

Lead Investor in This RoundMSA Capital (MSA) is also a shareholder in the Series B financing round; Zeng Yu, Founding Partner of MSA Capitalstated: “We are particularly bullish on the overall technical proficiency and execution capabilities of the AMADOR BIOSCIENCE team. As a CRO company with exceptional expertise in quantitative pharmacology and bioanalysis, AMADOR BIOSCIENCE is poised to see its unique technological capabilities gain broader application value and market potential, driven by the growing number of original innovation and first-in-class pharmaceutical projects in China. Furthermore, as a global CRO with a presence in multiple countries, including the United States and Europe, AMADOR BIOSCIENCE exemplifies the type of innovative company that Magic Stone Alternative Investment favors—leveraging globalization to expand service capabilities and clientele. Concurrently with this investment, AMADOR BIOSCIENCE completed the acquisition of the U.S.-based company A2PG, marking a highly beneficial step in its internationalization strategy. We believe this is just the beginning; Dr. Wang Bing and his team are fully capable of building upon the experience gained from this acquisition. We look forward to AMADOR BIOSCIENCE continuously enhancing its regional business coverage and establishing a more comprehensive service system, thereby setting a benchmark for the internationalization of Chinese CRO companies.”

MSA Capital is a private equity investment firm with deep roots in China and a global outlook, focusing on early-stage and growth-stage investments in key sectors such as healthcare, frontier technologies, internet, and consumer industries. Currently, MSA Capital manages over $1.7 billion in assets. Headquartered in Beijing, the firm maintains resident teams in the United States, the Middle East, and Africa. Leveraging its broad global perspective and profound insights into international markets, the team not only identifies high-quality investment opportunities but also helps portfolio companies rapidly expand into overseas markets by leveraging local resources.